Furthermore, the synergistic potential of multiple proteins (e.g., CDH17 and CEACAM5) may amplify risk through either additive or interactive mechanisms, which is consistent with the rationale for multi-target combination therapies in cancer 50. Here, CEACAM5 is linked to cancer.